List of Excipients in Branded Drug JANUMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	JANUMET	sitagliptin and metformin hydrochloride	0006-0078	ALUMINUM OXIDE
Merck Sharp & Dohme LLC	JANUMET	sitagliptin and metformin hydrochloride	0006-0078	CARNAUBA WAX
Merck Sharp & Dohme LLC	JANUMET	sitagliptin and metformin hydrochloride	0006-0078	CELLULOSE, MICROCRYSTALLINE

JANUMET Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Patent Risk

Last updated: August 16, 2026

Janumet combines sitagliptin phosphate and metformin hydrochloride in an oral fixed-dose tablet. Its commercial durability depends less on the active ingredients than on dose flexibility, gastrointestinal tolerability, tablet manufacturability, and the remaining protection around extended-release formulations and methods of use. The strongest excipient opportunities are in direct-compression systems, controlled-release polymers, low-nitrosamine manufacturing, and globally adaptable film-coating platforms.

What is Janumet and how is it positioned commercially?

Janumet is Merck's fixed-dose combination of the DPP-4 inhibitor sitagliptin and metformin. The product is approved for adults with type 2 diabetes as an adjunct to diet and exercise when both components are appropriate. Janumet XR provides once-daily extended-release dosing.

Product	Active ingredients	Dosage form	Commercial role
Janumet	Sitagliptin phosphate plus metformin hydrochloride	Immediate-release film-coated tablet	Twice-daily fixed-dose combination
Janumet XR	Sitagliptin phosphate plus extended-release metformin hydrochloride	Extended-release film-coated tablet	Once-daily regimen and adherence positioning
Januvia	Sitagliptin phosphate	Immediate-release tablet	DPP-4 inhibitor monotherapy or combination therapy
Generic combinations	Sitagliptin plus metformin	Immediate- or extended-release tablet	Price-driven competition after patent and regulatory barriers decline

The key formulation challenge is combining a low-dose, moisture-sensitive crystalline drug with high-dose metformin in a tablet that remains mechanically robust and tolerable in the gastrointestinal tract. Metformin is associated with gastrointestinal adverse effects, while the total tablet mass can become substantial at higher strengths.

What excipients are used in Janumet tablets?

The FDA labeling identifies a conventional solid-dose excipient system for Janumet. The core generally uses microcrystalline cellulose, povidone, sodium lauryl sulfate, and sodium stearyl fumarate. The film coating uses polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxide colorants, depending on tablet strength and product presentation.[1]

Janumet excipient functions

Excipient	Primary function	Strategic relevance
Microcrystalline cellulose	Diluent, dry binder, compressibility enhancer	Supports high-drug-load tablet manufacture
Povidone	Binder and granulation aid	Improves content uniformity and tablet strength
Sodium lauryl sulfate	Wetting and dissolution aid	Supports dispersion of the active ingredients
Sodium stearyl fumarate	Lubricant	Reduces sticking and ejection force
Polyvinyl alcohol	Film-forming coating polymer	Provides coating integrity and appearance
Polyethylene glycol	Plasticizer	Improves coating flexibility
Talc	Anti-tacking and coating aid	Supports high-speed coating
Titanium dioxide	Opacifier and pigment	Controls appearance and light protection
Iron oxides	Colorants	Differentiates strengths and reduces dispensing errors

The commercial lesson is that Janumet does not rely on a highly exotic excipient architecture. This creates a relatively accessible generic manufacturing pathway for immediate-release products. The difficulty increases with higher tablet loads, dissolution control, process validation, and extended-release metformin performance.

What excipients protect the extended-release version of Janumet?

Janumet XR requires a release-controlling matrix or multilayer architecture capable of delivering sitagliptin and metformin with different dissolution behaviors. Metformin hydrochloride is highly soluble and present at a high dose. A simple immediate-release blend can produce rapid drug release and unacceptable gastrointestinal exposure patterns.

Potential excipient strategies for Janumet XR include:

• Hydrophilic matrix polymers such as hypromellose.
• High-viscosity cellulose ethers for release control.
• Povidone or copovidone for binding and granulation.
• Microcrystalline cellulose for tablet structure.
• Sodium stearyl fumarate or comparable lubricants.
• Functional film coatings that limit moisture ingress without materially altering release.
• Multilayer tablets separating sitagliptin and metformin release environments.

The primary technical barrier is not merely selecting a polymer. It is matching dissolution across multiple strengths while controlling tablet size, swelling, erosion, compression force, and food-effect behavior. A generic developer that uses a different formulation can avoid literal copying of a branded composition, but it still must establish pharmaceutical equivalence and bioequivalence under FDA requirements.

What commercial opportunities exist for Janumet excipients?

1. High-load direct-compression platforms

The largest near-term opportunity is a high-load direct-compression platform for sitagliptin/metformin immediate-release tablets. Suppliers can compete with:

• Co-processed microcrystalline cellulose systems.
• Spray-dried mannitol or lactose blends.
• Low-moisture binders.
• Lubricants with reduced dissolution impact.
• Granulation systems that improve content uniformity at low sitagliptin loading.

A successful platform must maintain tablet hardness while avoiding excessive tablet weight. Metformin's high dose makes bulk density and powder flow commercially important.

2. Extended-release polymer systems

The strongest technical opportunity is in controlled-release excipients for Janumet XR alternatives. Polymer suppliers can provide differentiated systems that offer:

• Reproducible release across tablet strengths.
• Lower sensitivity to compression force.
• Reduced food-effect variability.
• Faster regulatory bridging across countries.
• Compatibility with high drug loads.

A platform that demonstrates robust release in both fed and fasted conditions has greater value than a polymer supported only by laboratory dissolution data.

3. Low-nitrosamine and impurity-controlled supply chains

Nitrosamine control is a commercial purchasing criterion for metformin-containing products. Risk can arise from active pharmaceutical ingredient manufacturing, recovered solvents, water systems, excipient impurities, and storage conditions. Excipients marketed with strong supplier qualification packages can gain share by providing:

• Nitrite and nitrate control data.
• Supplier change notification programs.
• Extractables and leachables documentation.
• Elemental impurity assessments.
• Lot-level traceability.
• ICH Q3D and ICH M7 support packages.

This opportunity applies to both branded lifecycle management and generic manufacturing.

4. Film-coating systems

Tablet color and strength differentiation are important for a multi-strength product. Ready-to-use coating systems can reduce process development time and improve global manufacturing consistency. Opportunities include titanium-dioxide-free systems, reduced-solvent coatings, high-opacity coatings, and formulations that provide improved moisture protection.

5. Pediatric and geriatric dosage forms

Janumet is primarily an adult tablet product, but the active combination creates potential opportunities in alternate delivery formats if regulatory and clinical requirements are met. These include:

• Smaller tablets.
• Sprinkle or multiparticulate formulations.
• Swallowing-friendly dosage forms.
• Modified-release granules.
• Unit-dose packaging with moisture protection.

Metformin's bitter taste, high dose, and gastrointestinal tolerability limit the attractiveness of liquid and chewable formats. The best opportunity is likely size reduction rather than a conventional oral liquid.

When does Janumet lose exclusivity?

Janumet's market protection is layered across active-ingredient patents, combination patents, extended-release patents, regulatory exclusivity, and litigation settlements. Sitagliptin's core composition protection has expired in the United States, while the combination and extended-release products have had later-dated protection.

Protection layer	Strategic effect
Sitagliptin compound patents	Protected the underlying DPP-4 inhibitor but no longer provides the principal barrier to all combination competition
Sitagliptin/metformin combination patents	Can delay or narrow generic fixed-dose entry
Extended-release formulation patents	More relevant to Janumet XR than to immediate-release Janumet
Method-of-use patents	May affect labeling, skinny-label strategies, and indication carve-outs
Pediatric exclusivity	Can add six months to qualifying patent or exclusivity periods
FDA regulatory exclusivity	Generally less important for this mature small-molecule product than listed patents

The relevant commercial date is the earliest legally permitted launch date for a specific generic product, not the expiration date of one patent in isolation. The date can vary by dosage form, strength, applicant, Paragraph IV certification, settlement terms, and court outcome.

What is the Orange Book status of Janumet?

The FDA Orange Book is the controlling public source for currently listed patents and exclusivity associated with approved Janumet products. Janumet and Janumet XR have separate approved applications and should be analyzed independently.[2]

A patent analyst should separate:

1. Patents listed against Janumet immediate-release tablets.
2. Patents listed against Janumet XR.
3. Patents listed against Januvia that do not necessarily block a sitagliptin/metformin product.
4. Drug substance patents that may apply to sitagliptin phosphate.
5. Formulation and method-of-use patents that may support different generic certifications.

A listed patent does not prove validity or infringement. A generic applicant can submit Paragraph III, Paragraph IV, or, where applicable, a section viii statement for a method-of-use patent. The commercial impact depends on the applicant's proposed label and the scope of the listed claims.

Which companies are challenging Janumet patents?

Generic competition has developed around sitagliptin and sitagliptin/metformin products through U.S. ANDA filings and international approvals. The relevant competitor set includes large generic manufacturers, regional suppliers, and companies that license or acquire ANDA rights.

For commercial diligence, the critical data points are:

• ANDA applicant identity.
• Product strength and release type.
• Paragraph IV filing date.
• Notice-letter recipients.
• District-court filing date.
• 30-month stay status.
• Tentative approval date.
• Settlement or license terms.
• Authorized-generic arrangements.
• Whether the applicant's label excludes protected uses.

A supplier selling excipients into this market should not assume that a litigation settlement permits immediate volume growth. Settlements can create staggered launches, limited licenses, or restrictions on specific strengths.

What patent litigation and settlements affect Janumet?

Janumet litigation risk is concentrated in three areas:

Combination-product claims

These claims may cover the use or composition of sitagliptin with metformin. They can be more relevant to a fixed-dose tablet than to separate coadministration of the two drugs.

Extended-release claims

Janumet XR may face claims directed to release profiles, matrix systems, multilayer structures, dosing schedules, or pharmacokinetic performance. Alternative excipient systems are particularly valuable here because they can support a non-infringing formulation while preserving bioequivalence.

Method-of-use claims

A generic applicant may carve out a protected indication or patient population if the remaining label still supports approval. This can reduce litigation exposure but may constrain marketing claims and pharmacy substitution.

Settlement agreements are commercially material because they can define launch dates, licensed manufacturers, permitted strengths, and the scope of authorized generic competition. Exact terms should be taken from court filings, FDA records, and company disclosures rather than inferred from approval timing.

What generic entry risks exist for Janumet?

Risk	Immediate-release Janumet	Janumet XR
Formulation complexity	Moderate	High
High drug-load manufacturing	High	High
Dissolution similarity	Moderate	High
Excipient substitution risk	Moderate	High
Patent design-around value	Moderate	High
Supply-chain qualification burden	Moderate	High
Price erosion after multiple entrants	High	Moderate initially

Immediate-release generic entry is likely to produce faster price erosion because the excipient system is conventional and several manufacturers can qualify similar processes. Janumet XR has greater technical friction, which can preserve value for qualified excipient platforms and contract manufacturers.

How strong is the Janumet patent estate?

Janumet's estate is stronger when evaluated by product and dosage form rather than by molecule alone.

Dimension	Assessment
Active ingredient	Mature and increasingly exposed to generic competition
Fixed-dose combination	More meaningful barrier than sitagliptin alone
Extended release	Stronger technical and regulatory barrier
Manufacturing process	Potentially useful if claims cover critical release or stability attributes
Method of use	Narrower commercial value because of label-carve-out strategies
Geographic coverage	Highly fragmented; U.S. and European positions require separate analysis
Excipient protection	Usually indirect, unless claims specify a matrix, coating, or release architecture

Excipient suppliers generally do not own the core pharmaceutical patent estate. Their value lies in enabling non-infringing formulation designs, shortening development timelines, and reducing regulatory risk.

How does Janumet compare with competing diabetes combinations?

Janumet competes with other DPP-4/metformin products, including linagliptin/metformin and saxagliptin/metformin combinations, as well as newer classes such as SGLT2 inhibitors and GLP-1 receptor agonists.

Product class	Excipient opportunity	Competitive pressure
Sitagliptin/metformin	High-load tablets and XR polymers	Generic price erosion
Linagliptin/metformin	Lower-dose DPP-4 formulation platforms	Branded and generic competition
SGLT2/metformin	Moisture control and bilayer systems	Strong clinical substitution
GLP-1 products	Injectable and device-related excipients	High growth but different technology
Metformin alone	Low-cost high-volume tablets	Intense commoditization

Janumet's strongest remaining commercial advantage is familiarity and fixed-dose convenience. Its weakest point is exposure to lower-priced generic combinations and therapeutic substitution toward newer agents.

What revenue exposure does Janumet create for excipient suppliers?

Revenue opportunity depends on volume, not excipient price. The core excipients are generally low-cost, widely available materials. Supplier differentiation requires technical service, regulatory documentation, and supply reliability.

The most defensible revenue pools are:

• Controlled-release polymers for Janumet XR-equivalent products.
• Co-processed excipients for high-load direct compression.
• Low-nitrite excipients and impurity-control packages.
• Global coating systems.
• Alternate suppliers qualified for dual sourcing.
• Contract development support for generic ANDA programs.

A supplier that sells only commodity microcrystalline cellulose or talc will face price competition. A supplier that provides a complete formulation platform, process window, regulatory package, and change-control support can capture higher-value development and qualification work.

What geographic opportunities exist for Janumet excipients?

The United States remains the most legally structured market because of Orange Book listings, ANDA certifications, and Paragraph IV litigation. Europe, Canada, Japan, India, Brazil, and other markets apply different patent and regulatory rules.

Geographic opportunities include:

• U.S. generic launches after settlement or patent expiry.
• European fixed-dose combinations subject to national patent and substitution rules.
• Emerging-market products using lower-cost excipient systems.
• Local manufacturing programs requiring regional supplier qualification.
• Dual-source strategies for products exposed to API or excipient disruption.

Global formulations must account for differences in excipient monographs, permitted colorants, titanium dioxide policy, labeling, and bioequivalence requirements.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are tablet weight, blend uniformity, sticking, hardness, dissolution control, and moisture management. The main intellectual-property barriers are formulation claims directed to extended release, combination composition, and selected use cases.

A practical design-around strategy is to:

1. Use a distinct release-controlling polymer system.
2. Separate sitagliptin and metformin processing steps where needed.
3. Avoid unnecessary overlap with claimed coating or matrix ratios.
4. Optimize dissolution against the reference product across all strengths.
5. Build nitrosamine controls into raw-material qualification.
6. Maintain evidence for formulation differences in the ANDA record.

Key Takeaways

• Janumet uses a conventional immediate-release excipient system centered on microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium stearyl fumarate, and a polyvinyl alcohol-based film coat.
• Janumet XR creates the stronger excipient opportunity because high-dose metformin requires controlled release and robust dissolution matching.
• Immediate-release generic competition is more exposed to rapid price erosion.
• The best supplier opportunities are controlled-release polymers, high-load direct-compression systems, low-nitrosamine excipients, and regulatory-grade coating platforms.
• Orange Book analysis must distinguish Janumet, Janumet XR, Januvia, combination patents, formulation patents, and method-of-use patents.
• Generic launch timing depends on Paragraph IV litigation, settlements, certifications, and dosage-form-specific patent barriers.
• Excipient suppliers gain strategic value by enabling design-around formulations and reducing ANDA development risk.

FAQs About Janumet Excipient and Commercial Strategy

What is the most important excipient for Janumet XR development?

A high-performance hydrophilic release-controlling polymer is usually the most important excipient category because metformin is present at high dose and is highly soluble.

Can a generic manufacturer use the same excipients as Janumet?

Yes, subject to applicable regulatory requirements. Using the same inactive ingredients does not by itself establish infringement, but the overall formulation, process, release profile, and patent claims must be assessed.

Is sodium lauryl sulfate necessary in a sitagliptin/metformin tablet?

Not necessarily. It can support wetting and dissolution, but a generic developer may replace it with another approach if the alternative produces acceptable content uniformity, dissolution, stability, and bioequivalence.

Does Janumet have biosimilar risk?

No. Janumet is a chemically synthesized small-molecule combination product. Its relevant competitive risks are generic ANDA products, authorized generics, formulation substitutes, and therapeutic competition from newer diabetes medicines.

Which Janumet formulation has the greatest licensing potential?

Janumet XR-equivalent technology has greater licensing potential than immediate-release Janumet because controlled-release performance, process robustness, and bioequivalence create more meaningful technical differentiation.

References

1. U.S. Food and Drug Administration. (2023). Janumet (sitagliptin and metformin hydrochloride) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). Janumet XR (sitagliptin and metformin hydrochloride extended-release) prescribing information. Merck Sharp & Dohme LLC.

4. U.S. Food and Drug Administration. (2021). Nitrosamine impurities in medications: Guidance for industry. https://www.fda.gov/drugs/drug-safety-and-availability

5. U.S. Food and Drug Administration. (2015). Metformin-containing products: Drug safety communication regarding vitamin B12 deficiency. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers